Home
HelpTest Code PBLI Plasma Cell Assessment, Blood
Reporting Name
Plasma Cell Assessment, BUseful For
Detecting peripheral blood involvement by plasma cell proliferative disorders
Establishing the diagnosis of and determining prognosis for plasma cell proliferative disorders
Testing Algorithm
The following algorithms are available:
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
Whole bloodShipping Instructions
Specimen must arrive within 3 days of collection.
Necessary Information
Date and time of collection are required.
Specimen Required
Container/Tube:
Preferred: Green top (sodium heparin)
Acceptable: Lavender top (EDTA)
Specimen Volume: 10 mL
Collection Instructions:
1. Do not centrifuge.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Minimum Volume
4 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole blood | Ambient (preferred) | 72 hours | |
| Refrigerated | 72 hours |
Special Instructions
Reference Values
An interpretive report will be provided.
Day(s) Performed
Monday through Saturday
Test Classification
This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88184-Flow cytometry, cell surface, cytoplasmic
88185 x 5-Each additional marker
88187-Flow cytometry, interpretation; 2 to 8 markers
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| PBLI | Plasma Cell Assessment, B | 86900-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 30388 | Blood Plasma Cell Light Chain | 86900-8 |
| 26838 | # Monotypic PCs per 150,000 events | 19099-1 |
| 26839 | PC Event Interpretation | 69052-9 |
Interpretation
In normal peripheral blood specimens, no clonal plasma cells are present (polytypic or too few to detect).
Plasma cells are CD38 and CD138 positive.
Normal (polyclonal, nonneoplastic) plasma cells are typically CD19-positive, whereas neoplastic (clonal) plasma cells typically are CD19-negative. CD19 expression is especially helpful in distinguishing clonal from nonclonal plasma cells when few analyzable cells are present.
CD45 may be expressed by both normal and neoplastic plasma cells. In some plasma cell proliferative disorders, there are both CD45-positive and CD45-negative subsets within the clonal cell population.
The evaluation of these antigens aids in the identification of abnormal plasma cells; however, they will not be reported independently.
Clinical Reference
1. Chakraborty R, Muchtar E, Kumar SK, et al. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer J. 2016;6(12):e512. doi:10.1038/ bcj.2016.117
2. Chakraborty R, Muchtar E, Kumar SK, et al. Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica. 2017;102(8):1439-1445
3. Evans LA, Jevremovic D, Nandakumar B, et al. Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. Am J Hematol. 2020;95(6):637-642. doi:10.1002/ajh.25773
4. Gonsalves WI, Jevremovic D, Nandakumar B, et al. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. Am J Hematol. 2020;95(3):310-315. doi:10.1002/ajh.25709
5. Ravi P, Kumar SK, Roeker L, et al. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer J. 2018;8(12):116
Report Available
1 to 2 daysMethod Name
Flow Cytometry
Forms
If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.